Medical Properties Trust, Inc. (MPT) Stock Price & How to Invest

Medical Properties Trust, Inc. trades on the New York Stock Exchange under the ticker MPT and is one of the largest owners of hospital real estate in the world. Its model is sale-leaseback: it buys hospital buildings from operators, then leases the property back under long-term net leases where the tenant covers taxes, insurance, and maintenance. The portfolio spans general acute care hospitals, behavioral health facilities, and post-acute sites across the United States and Europe, and revenue comes almost entirely from contractual rent plus interest on loans MPT has made to some of its tenants.

The investment picture is defined by a collapse from its former blue-chip status. After the 2024 bankruptcy of its largest tenant, Steward Health Care, MPT cut its dividend sharply, sold assets, and re-tenanted properties. The slide continued in 2026: as of October 16 the stock closed near $3.09, down about 39 percent year to date and about 41 percent over one year, for a market cap near $1.85 billion. Q1 2026 showed a net profit helped by one-time items, but Q2 2026 slipped back to a small net loss of about $2.6 million on roughly $259 million of revenue. In September MPT closed the sale of two Idaho hospitals to Intermountain Health affiliates for $371 million in cash to MPT and said most of it would go to debt reduction, against roughly $9.7 billion of total debt. It is a turnaround-and-deleveraging story, not a stable income staple, and the next report is due October 29, 2026.

MPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. The dividend is a live question: trailing net income is about -$32 million, the reported payout ratio is far above 100 percent, and a yield above 11 percent shows the market pricing in a possible cut. Asset sales reduce debt but also shrink rent, and BofA Securities trimmed its price target to $4.25 from $5 in August 2026. Hospital operators face reimbursement pressure, staffing shortages, and impairments. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT.

6 analysts publish price targets on MPT, averaging $5.12 against a $3.01 price as of October 2026, or +70.1%. The published targets run from $4.25 to $7.00, a moderate spread, and the ratings split 3 buy, 3 hold, 2 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MPT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Medical Properties Trust, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Tenant re-tenanting and rent recovery. MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and has guided toward more than $1 billion in annualized cash rent by year-end 2026. The most optimistic published target, $7.00, assumes this works close to its best case.

The case against. MPT carries roughly $9.7 billion of debt against a market cap near $1.85 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. The most pessimistic target, $4.25, is roughly what MPT is worth if this bites instead.

Read the full bull and bear case on MPT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Medical Properties Trust, Inc. (MPT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Medical Properties Trust, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.1 billion (+1.9% YoY latest qtr)
• Net income (TTM): ~-$32 million
• Market cap: ~$1.85 billion
• Stock price: ~$3.09 (YTD -39%)
• Dividend yield: ~11.6% (~$0.36/yr)
• Price to book: ~0.41x
• Total debt: ~$9.7 billion

MPT trades at about 0.41 times book value and 1.7 times sales, a steep discount to larger healthcare REITs like Welltower and Ventas, which reflects its leverage and tenant risk rather than a bargain hiding in plain sight. Q2 2026 brought about $259 million of revenue and a small net loss, after a Q1 profit that leaned on one-time tax and cash-rent items, and the $371 million Idaho hospital sale gives it cash to pay down debt at the cost of future rent. With a yield near 11.6 percent and Q3 results due October 29, the valuation is a classic high-yield, high-risk setup where the discount and the danger are two sides of the same coin.

Other names that sit close to MPT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MPT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MPT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MPT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MPT is a deep-value, high-yield hospital REIT where the investment picture turns almost entirely on tenant health and refinancing roughly $9.7 billion of debt, and the market's 2026 verdict (shares down about 39 percent year to date, yield above 11 percent) says it doubts the dividend.

Whether MPT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MPT a buy or a sell?, and where the stock could go from here in the MPT stock forecast.

For income investors, whether MPT pays a dividend and how the payout looks is covered in does MPT pay a dividend? And to weigh MPT against a peer, read the full side-by-side comparisons: MPT vs WELL and MPT vs VTR.